{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:06:56Z","timestamp":1790809616142,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21402235"],"award-info":[{"award-number":["21402235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31370958"],"award-info":[{"award-number":["31370958"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81461148033"],"award-info":[{"award-number":["81461148033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PLA Youth Medical Science and Technology Youth Development Program","award":["16QNP086"],"award-info":[{"award-number":["16QNP086"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejmech.2018.01.022","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T19:10:11Z","timestamp":1515611411000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL\/RANK interactions and reduces ovariectomy-induced bone loss in mice"],"prefix":"10.1016","volume":"145","author":[{"given":"Chao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Gang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.01.022_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2011.23","article-title":"Advances in osteoclast biology: old findings and new insights from mouse models","volume":"7","author":"Edwards","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib2","doi-asserted-by":"crossref","first-page":"11394","DOI":"10.1073\/pnas.0701971104","article-title":"Pathological role of osteoclast costimulation in arthritis-induced bone loss","volume":"104","author":"Ochi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.01.022_bib3","first-page":"569","article-title":"Diagnosis, and therapy, March 7-29, 2000: highlights of the conference","volume":"94","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","journal-title":"South. Med. J."},{"key":"10.1016\/j.ejmech.2018.01.022_bib4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejmech.2018.01.022_bib5","doi-asserted-by":"crossref","first-page":"11691","DOI":"10.1073\/pnas.0712239105","article-title":"The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I","volume":"105","author":"Kawatani","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.01.022_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.ejmech.2018.01.022_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00198-009-0924-z","article-title":"Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women","volume":"21","author":"Hiligsmann","year":"2010","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejmech.2018.01.022_bib8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.01.022_bib9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","article-title":"Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective","volume":"54","author":"Boonen","year":"2006","journal-title":"J.\u00a0Am. Geriatr. Soc."},{"key":"10.1016\/j.ejmech.2018.01.022_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1359\/JBMR.041214","article-title":"Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study","volume":"20","author":"Delmas","year":"2005","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00198-003-1544-7","article-title":"Undertreatment with anti-osteoporotic drugs after hospitalization for fracture","volume":"15","author":"Panneman","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejmech.2018.01.022_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2018.01.022_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2018.01.022_bib15","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2018.01.022_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.022_bib17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.01.022_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.01.022_bib19","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.01.022_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jbmr.2350","article-title":"Urokinase receptor mediates osteoclastogenesis via m-CSF release from osteoblasts and the c-Fms\/PI3K\/Akt\/NF-kappa B pathway in osteoclasts","volume":"30","author":"Anaraki","year":"2015","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib21","first-page":"1637","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma","volume":"61","author":"Michigami","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A\u00a0homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.022_bib23","doi-asserted-by":"crossref","first-page":"20551","DOI":"10.1074\/jbc.273.32.20551","article-title":"Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase","volume":"273","author":"Darnay","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib24","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.01.022_bib25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-002-8530-7","article-title":"Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis","volume":"59","author":"Bolon","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.01.022_bib26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.berh.2005.07.004","article-title":"Determinants of skeletal fragility","volume":"19","author":"Bouxsein","year":"2005","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2004.12.020","article-title":"The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management","volume":"27","author":"Felsenberg","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2018.01.022_bib28","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2013the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.01.022_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.10.007","article-title":"Role of RANKL in bone diseases","volume":"20","author":"Anandarajah","year":"2009","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2018.01.022_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2018.01.022_bib31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000106484","article-title":"Signaling axis in osteoclast biology and therapeutic targeting in the RANKL\/RANK\/OPG system","volume":"27","author":"Tanaka","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0105-2896.2005.00327.x","article-title":"Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system","volume":"208","author":"Tanaka","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2018.01.022_bib33","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib34","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.01.022_bib36","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib37","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2018.01.022_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14712598.6.10.1041","article-title":"RANK ligand inhibition with denosumab for the management of osteoporosis","volume":"6","author":"Lewiecki","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2018.01.022_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J.\u00a0Bone Miner. Metab"},{"key":"10.1016\/j.ejmech.2018.01.022_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1078155216628325","article-title":"Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis","volume":"23","author":"Yerram","year":"2017","journal-title":"J.\u00a0Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejmech.2018.01.022_bib42","doi-asserted-by":"crossref","first-page":"20281","DOI":"10.1073\/pnas.1011686107","article-title":"Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis","volume":"107","author":"Ta","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.01.022_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.01.022_bib44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4155\/fmc.10.259","article-title":"Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention","volume":"2","author":"Mason","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI22513","article-title":"A\u00a0TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss","volume":"116","author":"Aoki","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.01.022_bib46","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.1074\/jbc.M309690200","article-title":"Disabling of receptor activator of nuclear factor-\u03baB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in\u00a0vivo","volume":"279","author":"Cheng","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/0008-5472.CAN-06-1287","article-title":"An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma","volume":"67","author":"Heath","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.01.022_bib48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cbi.2012.12.016","article-title":"RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-kappaB activation and down regulating inflammatory cytokines","volume":"203","author":"Naidu","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2018.01.022_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4049\/jimmunol.1103387","article-title":"Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin","volume":"189","author":"Luan","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib50","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1021\/jo960917+","article-title":"Kinetics and equilibria of the thiol\/disulfide exchange reactions of somatostatin with glutathione","volume":"61","author":"Rabenstein","year":"1996","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0076-6879(95)51107-5","article-title":"Thiol\/disulfide exchange equilibria and disulfide bond stability","volume":"251","author":"Gilbert","year":"1995","journal-title":"Meth. Enzymol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib52","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.bmc.2012.02.030","article-title":"Synthesis and evaluation of disulfide bond mimetics of amylin-(1-8) as agents to treat osteoporosis","volume":"20","author":"Kowalczyk","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib53","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1021\/jm801577r","article-title":"Synthesis and antibacterial activities of N-glycosylated derivatives of tyrocidine A, a macrocyclic peptide antibiotic","volume":"52","author":"Hu","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/ar2325","article-title":"Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study","volume":"9","author":"Tat","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2018.01.022_bib55","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1998.2189","article-title":"Isomorphous replacement of cystine with selenocystine in endothelin: oxidative refolding, biological and conformational properties of [Sec3, Sec11, Nle7]-endothelin-1","volume":"284","author":"Pegoraro","year":"1998","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib56","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1039\/C5SC04187B","article-title":"Synthesis and activity of a diselenide bond mimetic of the antimicrobial protein caenopore-5","volume":"7","author":"Medini","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2018.01.022_bib57","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1039\/C6RA26617G","article-title":"Diaminodiacid-based synthesis of macrocyclic peptides using 1,2,3-triazole bridges as disulfide bond mimetics","volume":"7","author":"Guo","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.01.022_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ni0302-221","article-title":"NF-kappaB at the crossroads of life and death","volume":"3","author":"Karin","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2018.01.022_bib59","doi-asserted-by":"crossref","DOI":"10.1039\/C7SC02420G","article-title":"A\u00a0novel peptide stapling strategy enables the retention of ring-closing amino acid side chains for the Wnt\/\u03b2-catenin signalling pathway","author":"Wu","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2018.01.022_bib60","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.str.2012.08.030","article-title":"RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor","volume":"20","author":"Nelson","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2018.01.022_bib61","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F","article-title":"Chemistry, biology, and medicine of the glycopeptide antibiotics","volume":"38","author":"Nicolaou","year":"1999","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.01.022_bib62","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1021\/cr030103a","article-title":"Glycopeptide and lipoglycopeptide antibiotics","volume":"105","author":"Kahne","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.01.022_bib63","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1021\/jm901265h","article-title":"Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors","volume":"53","author":"Ferreira","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib64","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejmech.2008.02.047","article-title":"Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates","volume":"44","author":"da Silva","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.022_bib65","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/74719","article-title":"New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population","volume":"6","author":"Brandt","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2018.01.022_bib66","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1016\/j.tet.2006.06.001","article-title":"Synthetic utility of glycosyl triazoles in carbohydrate chemistry","volume":"62","author":"Wilkinson","year":"2006","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2018.01.022_bib67","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1002\/anie.201005846","article-title":"Maintaining biological activity by using triazoles as disulfide bond mimetics","volume":"50","author":"Holland-Nell","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.01.022_bib68","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1002\/anie.201008142","article-title":"\u201cTriazole bridge\u201d: disulfide-bond replacement by ruthenium-catalyzed formation of 1,5-disubstituted 1,2,3-triazoles","volume":"50","author":"Empting","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.01.022_bib69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/rheumatology\/kes259","article-title":"Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases","volume":"52","author":"Kikuta","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2018.01.022_bib70","doi-asserted-by":"crossref","first-page":"9747","DOI":"10.1016\/j.biomaterials.2014.08.007","article-title":"Selective osteogenesis by a synthetic mineral inducing peptide for the treatment of osteoporosis","volume":"35","author":"Park","year":"2014","journal-title":"Biomaterials"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418300229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418300229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T18:53:53Z","timestamp":1733770433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418300229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":70,"alternative-id":["S0223523418300229"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.022","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL\/RANK interactions and reduces ovariectomy-induced bone loss in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}